Medipharm Labs Applies for Nasdaq Listing

Medipharm Labs (TSX: LABS) announced this morning that it has submitted an application for listing on the Nasdaq stock exchange. If approved, the equity will be dual listed to allow for investors to more easily hold a position in the firms equity.

Once coveted as a golden trophy by cannabis sector investors, cross listing to US markets has had little positive effect on cannabis focused issuers that have made the cut. While the listing is viewed as enabling more investors to take a stake in the firm, its also opens the firm to heavier selling pressure through more active options trading and short selling. Once viewed as a sentiment boosting move, cross listing, at least for cannabis companies, is a rather uninspiring event in most instances.

Yet, numerous issuers are still chasing the prospect of being listed on a big board exchange to provide additional liquidity to their equity. Notable attempts by Canadian issuers that have yet to see results include The Green Organic Dutchman (TSX: TGOD), who applied in August for a dual listing, and Aleafia Health (TSX: ALEF) who applied in October 2018 for listing. No progress has been made in either instance in regards to uplisting. Smaller firms, such as FSD Pharma (CSE: HUGE) and Namaste Technologies (TSXV: N) have previously mentioned such aspirations as well, however these are general viewed as “long shot attempts” by investors.

We are thrilled to be entering the next phase of growth at MediPharm Labs including cross-listing on the NASDAQ, one of the world’s foremost exchanges for emerging markets and technology, such as the burgeoning cannabis sector. We are thrilled to be entering the next phase of growth at MediPharm Labs including cross-listing on the NASDAQ, one of the world’s foremost exchanges for emerging markets and technology, such as the burgeoning cannabis sector.

Pat McCutcheon, Chief Executive Officer, MediPharm Labs

No timeline has been provided by Medipharm Labs for a potential approval of the listing of its shares. The news of the application for cross listing follows yesterday’s news of the firm replacing the CFO with a former executive from that of George Weston.

Medipharm Labs closed yesterdays session at $4.53 on the TSX Venture.


Information for this briefing was found via Sedar and Medipharm Labs.. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Medipharm Signs Danish White Label Agreement

Medipharm Labs (TSX: LABS) continues to expand its international presence, this morning announcing that it...

Friday, September 25, 2020, 08:49:28 AM

MediPharm Labs Posts Q3 Revenues of $5.4 Million, Continues To Post Negative Gross Margins

MediPharm Labs (TSX: LABS) this morning reported its third quarter financial results, posting revenues of...

Monday, November 15, 2021, 08:54:23 AM

Harvest Moon: Valens Company VS Medipharm Labs – Share Price Indicators

Of the 100 companies in the BI Global Cannabis Competitive Peers index tracked in 2019,...

Sunday, June 21, 2020, 05:00:00 PM

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Canaccord Genuity Raises Medipharm Labs’ Price Target To C$2.50

On Monday Medipharm Labs (TSX: LABS) announced an exclusive medical cannabis partnership with the European...

Tuesday, October 6, 2020, 01:29:18 PM